1. Gross, E.; Seck, K.; Kiechle, M. Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance. Zentralbl. Gynakol. 2002, 124 (12), 574-579.

2. Van Kuilenburg, A.B.; Meinsma, R.; Zoetekouw, L.; Van Gennip, A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimi-dine dehydrogenase deficiency: High prevalence of the IVS14+ 1g>a mutation. Int. J. Cancer 2002, 101 (3), 253258.

3. Van Kuilenburg, A.B.; Meinsma, R.; Zoetekouw, L.; Van Gennip, A.H. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002, 12 (7), 555-558.

4. Gardiner, S.J.; Begg, E.J.; Robinson, B.A. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React. Toxicol. Rev. 2002, 21 (1-2), 1-16.

5. Raida, M.; Schwabe, W.; Hausler, P.; Van Kuilenburg, A.B.; Van Gennip, A.H.; Behnke, D.; Hoffken, K. Prevalence of a common point mutation in the dihydropy-rimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 2001, 7 (9), 2832-2839.

6. van Kuilenburg, A.B.; Muller, E.W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.; Waterham, H.R.; Baas, F.; Richel, D.J.; van Gennip, A.H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 2001, 7 (5), 1149-1153.

7. Tai, H.L.; Fessing, M.Y.; Bonten, E.J.; Yanishevsky, Y.; d'Azzo, A.; Krynetski, E.Y.; Evans, W.E. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999, 9 (5), 641-650.

8. Evans, W.E. Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations. J. Pediatr. Hematol. Oncol. 2002, 24 (5), 335336.

9. Fessing, M.Y.; Krynetski, E.Y.; Schuetz, J.D.; Evans, W.E. Structural and functional analysis of the human TPMT gene promoter. Adv. Exp. Med. Biol. 1998, 431, 315318.

10. McLeod, H.L.; Krynetski, E.Y.; Relling, M.V.; Evans, W.E. Genetic polymorphism of thiopurine methyltransfer-ase and its clinical relevance for childhood acute lym-phoblastic leukemia. Leukemia 2000, 14 (4), 567-572.

11. McLeod, H.L.; Coulthard, S.; Thomas, A.E.; Pritchard, S.C.; King, D.J.; Richards, S.M.; Eden, O.B.; Hall, A.G.; Gibson, B.E. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 1999, 105 (3), 696-700.

12. Evans, W.E.; Horner, M.; Chu, Y.Q.; Kalwinsky, D.; Roberts, W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyl-transferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 1991, 119 (6), 985-989.

13. Tai, H.L.; Krynetski, E.Y.; Yates, C.R.; Loennechen, T.; Fessing, M.Y.; Krynetskaia, N.F.; Evans, W.E. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 1996, 58 (4), 694-702.

14. Otterness, D.M.; Szumlanski, C.L.; Wood, T.C.; Wein-shilboum, R.M. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J. Clin. Invest. 1998, 101 (5), 1036-1044.

15. Spire-Vayron de la Moureyre, C.; Debuysere, H.; Mastain,

B.; Vinner, E.; Marez, D.; Lo Guidice, J.M.; Chevalier, D.; Brique, S.; Motte, K.; Colombel, J.F.; Turck, D.; Noel, C.; Flipo, R.M.; Pol, A.; Lhermitte, M.; Lafitte, J.J.; Libersa,

C.; Broly, F. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 1998, 125 (4), 879-887.

16. Iqbal, S.; Lenz, H.J. Determinants of prognosis and response to therapy in colorectal cancer. Curr. Oncol. Rep. 2001, 3 (2), 102-108.

17. Van Aken, J.; Schmedders, M.; Feuerstein, G.; Kollek, R. Prospects and limits of pharmacogenetics: The Thiopurine Methyl Transferase (TPMT) experience. Am. J. Pharma-cogenomics 2003, 3 (3), 149-155.

18. Relling, M.V.; Hancock, M.L.; Rivera, G.K.; Sandlund, J.T.; Ribeiro, R.C.; Krynetski, E.Y.; Pui, C.H.; Evans, W.E. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 1999, 91 (23), 2001-2008.

19. Wasserman, E.; Myara, A.; Lokiec, F.; Goldwasser, F.; Trivin, F.; Mahjoubi, M.; Misset, J.L.; Cvitkovic, E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Ann. Oncol. 1997, 8 (10), 1049-1051.

20. Iyer, L.; King, C.D.; Whitington, P.F.; Green, M.D.; Roy, S.K.; Tephly, T.R.; Coffman, B.L.; Ratain, M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite

(SN-38) in human liver microsomes. J. Clin. Invest. 1998, 101 (4), 847 - 854.

21. Iyer, L.; Das, S.; Janisch, L.; Wen, M.; Ramirez, J.; Karrison, T.; Fleming, G.F.; Vokes, E.E.; Schilsky, R.L.; Ratain, M.J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002, 2 (1), 43-47.

22. Iyer, L.; Hall, D.; Das, S.; Mortell, M.A.; Ramirez, J.; Kim, S.; Di Rienzo, A.; Ratain, M.J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 1999, 65 (5), 576-582.

23. Innocenti, F.; Grimsley, C.; Das, S.; Ramirez, J.; Cheng, C.; Kuttab-Boulos, H.; Ratain, M.J.; Di Rienzo, A. Haplotype structure of the UDP-lucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacoge-netics 2002, 12 (9), 725-733.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment